C Pellat-Deceunynck

Summary

Country: France

Publications

  1. ncbi request reprint Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells
    C Pellat-Deceunynck
    Institute National de la Santé et de la Recherche Médicale U463, Institut de Biologie, Nantes, France
    Clin Cancer Res 5:705-9. 1999
  2. ncbi request reprint The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells
    C Pellat-Deceunynck
    INSERM U463, Institut de Biologie, Nantes, France
    Eur J Immunol 30:803-9. 2000
  3. ncbi request reprint Tumour-associated antigens in multiple myeloma
    Catherine Pellat-Deceunynck
    INSERM U463, Equipe Labellisee par la Ligue Contre le Cancer, Institut de Biologie, Nantes, France
    Br J Haematol 120:3-9. 2003
  4. ncbi request reprint Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression
    C Pellat-Deceunynck
    Inserm UMR463, Institut de Biologie, 44093 Nantes Cedex 01, France
    Blood Cells Mol Dis 32:293-301. 2004
  5. ncbi request reprint Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells
    C Pellat-Deceunynck
    Laboratoire d Oncogénèse Immunohématologique, Institut de Biologie, Nantes, France
    Blood 84:2597-603. 1994
  6. ncbi request reprint Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells
    S Le Gouill
    Institut National de la Santé et de la Recherche Médicale Unité 463, Institut de Biologie, Nantes, France
    Leukemia 16:1664-7. 2002
  7. ncbi request reprint Interleukin-6 is a growth factor for nonmalignant human plasmablasts
    G Jego
    , Institut de Biologie, Nantes, France
    Blood 97:1817-22. 2001
  8. pmc Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
    D Chiron
    1 INSERM, UMR 892, Centre de Recherches en Cancérologie Nantes Angers, Nantes, France 2 UFR Médecine et Techniques Médicales, Universite de Nantes, Nantes, France 3 CNRS, UMR 6299, Nantes, France
    Blood Cancer J 3:e120. 2013
  9. pmc The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
    G Descamps
    INSERM, U892, Univ Nantes, CNRS, UMR 6299, Nantes, F 44000, France
    Br J Cancer 106:1660-7. 2012
  10. ncbi request reprint Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors
    G Jego
    INSERM, U601, Nantes, France
    Leukemia 20:1130-7. 2006

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells
    C Pellat-Deceunynck
    Institute National de la Santé et de la Recherche Médicale U463, Institut de Biologie, Nantes, France
    Clin Cancer Res 5:705-9. 1999
    ..This seems to be the first demonstration of myeloma-specific pCTL in peripheral blood T cells of patients with multiple myeloma...
  2. ncbi request reprint The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells
    C Pellat-Deceunynck
    INSERM U463, Institut de Biologie, Nantes, France
    Eur J Immunol 30:803-9. 2000
    ..HLA-A1 cytotoxic T lymphocytes efficiently killed MAGE-1+HLA-A1+ MDN myeloma cells. Taken together, our data show that mage-1 and mage-3 could constitute specific targets for tumor immunotherapy of MM patients...
  3. ncbi request reprint Tumour-associated antigens in multiple myeloma
    Catherine Pellat-Deceunynck
    INSERM U463, Equipe Labellisee par la Ligue Contre le Cancer, Institut de Biologie, Nantes, France
    Br J Haematol 120:3-9. 2003
  4. ncbi request reprint Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression
    C Pellat-Deceunynck
    Inserm UMR463, Institut de Biologie, 44093 Nantes Cedex 01, France
    Blood Cells Mol Dis 32:293-301. 2004
    ..In conclusion, proliferation is linked to plasma-cell generation and a CD45bright phenotype is the hallmark of the most proliferating normal, reactive as well as malignant plasma cells...
  5. ncbi request reprint Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells
    C Pellat-Deceunynck
    Laboratoire d Oncogénèse Immunohématologique, Institut de Biologie, Nantes, France
    Blood 84:2597-603. 1994
    ..Our data strongly suggest that both disease activity and medullary homing (or not) are correlated with the expression of CD19, CD40, CD28, and CD56 on human myeloma cells...
  6. ncbi request reprint Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells
    S Le Gouill
    Institut National de la Santé et de la Recherche Médicale Unité 463, Institut de Biologie, Nantes, France
    Leukemia 16:1664-7. 2002
    ..The induction of apoptosis by R115777 in myeloma cells and its implication in the regulation of JAK/STAT signalling suggest that R115777 might be an interesting therapeutical approach in MM...
  7. ncbi request reprint Interleukin-6 is a growth factor for nonmalignant human plasmablasts
    G Jego
    , Institut de Biologie, Nantes, France
    Blood 97:1817-22. 2001
    ..Finally, IL-6 enhanced the proliferation (2-fold increase) of IL-2-generated plasmablasts. In conclusion, the data indicate that IL-6 is a growth factor for nonmalignant human plasmablasts...
  8. pmc Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
    D Chiron
    1 INSERM, UMR 892, Centre de Recherches en Cancérologie Nantes Angers, Nantes, France 2 UFR Médecine et Techniques Médicales, Universite de Nantes, Nantes, France 3 CNRS, UMR 6299, Nantes, France
    Blood Cancer J 3:e120. 2013
    ..This study highlights the autocrine role of IGF1 in myeloma cells and reinforces the interest in targeting IGF1R in IGFR1(+) CD45(+/-) patients, such as MMSET(+) patients...
  9. pmc The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
    G Descamps
    INSERM, U892, Univ Nantes, CNRS, UMR 6299, Nantes, F 44000, France
    Br J Cancer 106:1660-7. 2012
    ..As multiple myeloma is an incurable disease that requires new therapeutic approaches, we investigated whether targeting the translation initiation pathway could be a target for myeloma therapy...
  10. ncbi request reprint Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors
    G Jego
    INSERM, U601, Nantes, France
    Leukemia 20:1130-7. 2006
    ..Thus, TLR expression and function are not restricted to the cells of the immune system and could be of advantage for cancer cells. In MM, recurrent infections could promote tumor growth and favor escape from standard therapies...
  11. ncbi request reprint A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy
    Regis Bataille
    Myeloma Basic Research Group, INSERM U463 and Central Laboratory of Hematology, Nantes, France
    Immunol Rev 194:105-11. 2003
    ..Finally, this model presents MM as a self-renewing plasma cell disease, although the first oncogenic events such as 14q32 translocations clearly occur earlier in a B cell...
  12. ncbi request reprint The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells
    Géraldine Descamps
    Institut National de la Santé et de la Recherche Médicale Unité 601, Ligue Nationale contre le Cancer Label, Nantes, France
    J Immunol 173:4953-9. 2004
    ..Thus, strategies that block IGF-1R signaling and consequently the Akt/PI3K pathway could be a priority in the treatment of patients with multiple myeloma, especially those lacking CD45 expression that have a very poor clinical outcome...
  13. ncbi request reprint Phenotypic characterization of the human myeloma cell growth fraction
    Nelly Robillard
    Institut National de la Santé et de la Recherche Médicale UMR601, Département de Recherche en Cancérologie, Nantes, France
    Blood 105:4845-8. 2005
    ..Among all of these molecules, only CD11a was exclusively expressed by CD45(bright) proliferating myeloma cells. In conclusion, proliferating myeloma cells are characterized by the specific CD45(bright) CD11a(pos) Bcl-2(low) phenotype...
  14. ncbi request reprint Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells
    Madeleine Collette
    INSERM, U601, Département de Recherche en Cancérologie, LNC Label, Institut de Biologie, 9 quai Moncousu, 44000 Nantes, France
    Eur Cytokine Netw 18:120-6. 2007
    ..The poor outcome of CD45- myeloma patients could be related to the capacity of CD45-myeloma cells to take advantage of multiple growth factors...
  15. ncbi request reprint The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy
    Regis Bataille
    INSERM, U601, Nantes, France
    Haematologica 91:1234-40. 2006
    ..Finally, this review presents data from normal PC up to human myeloma cell lines in order to: (i) define different entities of MM based on expression of CD19, CD20, CD27 and CD117; and (ii) identify new therapeutic targets...
  16. ncbi request reprint Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells
    Alexandrine Geffroy-Luseau
    Inserm UMR601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 01, France
    Int Immunol 17:1193-200. 2005
    ..Cold target competition and acid elution experiments confirmed that myeloma cell recognition was peptide dependent...
  17. ncbi request reprint CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis
    Regis Bataille
    INSERM UMR 601, Institute of Biology, Nantes, France
    Leuk Res 32:379-82. 2008
    ..In conclusion, CD117 (c-kit) is aberrantly expressed on a subset of MGUS and MM with a more indolent presentation and is functionally antinomic to CD221 (IGF-1R). CD117 expression could be related to a specific oncogenic pathway in MM...
  18. ncbi request reprint Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
    Emmanuelle Menoret
    Institut National de la Sante et de la Recherche Medicale, Unite 601, Nantes, F 44000, France
    Blood 108:1346-52. 2006
    ..Taken together, our data clearly encourage clinical trials of anti-TRAILR1 mAb in multiple myeloma, especially for patients whose disease is in relapse, at the time of drug resistance...
  19. doi request reprint Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
    Andy C Rawstron
    HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK
    Haematologica 93:431-8. 2008
    ....
  20. ncbi request reprint Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma
    Laurent Garderet
    Inserm and EA1638, Faculte de Medecine Saint Antoine, Universite Pierre et Marie Curie Paris 6, Paris, France
    Leuk Lymphoma 47:1340-7. 2006
    ..In conclusion, the T-cell response to pulsed DCs was very weak or absent. There are clinical and technical reasons that could explain, in part, this lack of response...
  21. pmc Toll-like receptors: lessons to learn from normal and malignant human B cells
    David Chiron
    INSERM U892, Nantes, France
    Blood 112:2205-13. 2008
    ..Special attention will be focused on the growth-promoting effects of TLR ligands on leukemic B cells and their potential clinical impact...